Claro Advisors LLC Increases Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Claro Advisors LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 16.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,555 shares of the biopharmaceutical company’s stock after purchasing an additional 1,187 shares during the period. Claro Advisors LLC’s holdings in Gilead Sciences were worth $717,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of GILD. UniSuper Management Pty Ltd grew its stake in Gilead Sciences by 11.0% during the first quarter. UniSuper Management Pty Ltd now owns 195,489 shares of the biopharmaceutical company’s stock valued at $14,320,000 after acquiring an additional 19,398 shares in the last quarter. Bessemer Group Inc. grew its stake in Gilead Sciences by 23.7% during the first quarter. Bessemer Group Inc. now owns 121,072 shares of the biopharmaceutical company’s stock valued at $8,868,000 after acquiring an additional 23,213 shares in the last quarter. Lake Street Advisors Group LLC grew its stake in Gilead Sciences by 32.8% during the first quarter. Lake Street Advisors Group LLC now owns 18,044 shares of the biopharmaceutical company’s stock valued at $1,322,000 after acquiring an additional 4,461 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its stake in Gilead Sciences by 1.2% during the first quarter. CANADA LIFE ASSURANCE Co now owns 1,809,036 shares of the biopharmaceutical company’s stock valued at $132,616,000 after acquiring an additional 21,224 shares in the last quarter. Finally, Natixis grew its stake in Gilead Sciences by 40.5% during the first quarter. Natixis now owns 152,226 shares of the biopharmaceutical company’s stock valued at $11,151,000 after acquiring an additional 43,916 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 4.0 %

Shares of GILD opened at $88.40 on Monday. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The company has a 50-day moving average of $86.68 and a 200 day moving average of $76.11. The firm has a market capitalization of $110.17 billion, a price-to-earnings ratio of 982.22, a PEG ratio of 2.72 and a beta of 0.17. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 0.82.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter last year, the business posted $2.29 EPS. On average, research analysts expect that Gilead Sciences, Inc. will post 4.38 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 3.48%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 56,947 shares of company stock valued at $4,968,674. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on GILD. BMO Capital Markets raised their target price on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Oppenheimer increased their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a research report on Friday, August 9th. Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Finally, Wolfe Research started coverage on shares of Gilead Sciences in a research report on Friday. They set an “outperform” rating and a $110.00 price objective for the company. Eleven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $93.86.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.